Aarkstore.com announces, a new market research report is available in its vast collection:
Cancer Diagnostic Testing World Markets
http://www.aarkstore.com/reports/Cancer-Diagnostic-Testing-World-Markets-1303.ht
Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position.
Table of Contents :
1. Overview 8
1.1 Statement of Report 8
1.2 About This Report 8
1.3 Scope of the Report 9
1.4 Objectives 10
1.5 Methodology 10
1.6 Executive Summary 11
2. Introduction to Cancer Biology and the Diagnostic Industry 14
2.1 Cancer 14
2.1.1 The Disease 14
2.1.2 Metastasis 14
2.1.3 Demographics and Statistics of Cancer 14
2.2 The Drivers of the Biotech and Diagnostics Industry 19
2.2.1 Technological Innovation 20
2.2.2 Government Funding 21
2.3 Outlook for Tumor Markers 21
3. Tumor Markers Market Segment Analysis: Size, Growth and Share 23
3.1 Market Description 24
3.2 Clinical Diagnostic Serum Based Cancer Markers 31
3.3 PSA Testing Market Size 32
3.4 DNA Markers 33
3.5 Serum Proteins 33
3.6 Enzymes 34
3.7 Occult Blood 34
3.8 Histology and In Situ Hybridization (ISH) 35
3.9 Cervical Cytology 36
3.10 Immunohistochemistry 38
3.11 In Vivo Detection Cancer Products 39
3.12 Radionuclides and X-Ray Detection Products 39
3.13 Human Papillomavirus (HPV) Testing 39
3.14 Bladder Cancer Testing 43
3.15 Tumor Assays for Adjuvant Chemotherapy 46
For More Related Reports Please follow the link :
http://www.aarkstore.com/search/viewresults.asp?search=Cancer &PubId=&pagenum=1
http://www.aarkstore.com/market-sector-reports/showgroupreports.asp?GroupId=136&
Aarkstore.com announces, a new market research report is available in its vast collection:
Cancer Diagnostic Testing World Markets
http://www.aarkstore.com/reports/Cancer-Diagnostic-Testing-World-Markets-1303.ht
Cancer testing is one of the most important growth opportunities for the next three to five years in the diagnostics segment. The National Cancer Institute estimates that about ten million Americans have or have had some form of cancer. Overall costs of the disease are $126 billion annually. Pharmaceutical companies are developing more than 300 new medicines for cancer, some of which are in development for more than one type of the disease, for a total of more than 500 ongoing R&D projects. The goal of this Publications report is to review the market for tumor marker testing equipment and supplies using screening reagents and instruments for analysis of individual components in blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including: the physician office labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of testing and the factors that influence purchases are discussed. The report surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the clinical point-of-care market in the U.S. Each company is discussed in depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company’s market position.
Table of Contents :
1. Overview 8
1.1 Statement of Report 8
1.2 About This Report 8
1.3 Scope of the Report 9
1.4 Objectives 10
1.5 Methodology 10
1.6 Executive Summary 11
2. Introduction to Cancer Biology and the Diagnostic Industry 14
2.1 Cancer 14
2.1.1 The Disease 14
2.1.2 Metastasis 14
2.1.3 Demographics and Statistics of Cancer 14
2.2 The Drivers of the Biotech and Diagnostics Industry 19
2.2.1 Technological Innovation 20
2.2.2 Government Funding 21
2.3 Outlook for Tumor Markers 21
3. Tumor Markers Market Segment Analysis: Size, Growth and Share 23
3.1 Market Description 24
3.2 Clinical Diagnostic Serum Based Cancer Markers 31
3.3 PSA Testing Market Size 32
3.4 DNA Markers 33
3.5 Serum Proteins 33
3.6 Enzymes 34
3.7 Occult Blood 34
3.8 Histology and In Situ Hybridization (ISH) 35
3.9 Cervical Cytology 36
3.10 Immunohistochemistry 38
3.11 In Vivo Detection Cancer Products 39
3.12 Radionuclides and X-Ray Detection Products 39
3.13 Human Papillomavirus (HPV) Testing 39
3.14 Bladder Cancer Testing 43
3.15 Tumor Assays for Adjuvant Chemotherapy 46
For More Related Reports Please follow the link :
http://www.aarkstore.com/search/viewresults.asp?search=Cancer &PubId=&pagenum=1
http://www.aarkstore.com/market-sector-reports/showgroupreports.asp?GroupId=136&